Purifying tcr-modified t cells using tcr-specific car-nk cells

Abstract

The invention relates to a genetically modified natural killer (NK) cell, comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein said CAR comprises an extracellular antigen-binding domain that specifically binds a component of a T cell receptor complex, and wherein said nucleic acid sequence is integrated in the NK cell genome without a viral vector. Further relating to a method for destroying a T cell, comprising an endogenous TCR expressed and/or presented on the cell surface, the method comprising contacting said T cell to be destroyed with a genetically modified natural killer (NK) cell of the invention. Further relating to a method for manufacturing a therapeutic genetically modified T cell, to the resulting in vitro cell population, and to the in vitro cell population for use in the treatment and/or prevention of a medical condition susceptible to T cell therapy.

Dependencies are inferred from the claim text.